U.S. markets open in 9 hours 25 minutes

Arcus Biosciences, Inc. (RCUS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
28.57-0.02 (-0.07%)
At close: 04:00PM EDT
28.50 -0.07 (-0.25%)
After hours: 04:18PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Hanging Man

Hanging Man

Previous Close28.59
Bid11.44 x 1100
Ask29.99 x 1000
Day's Range28.30 - 29.61
52 Week Range16.74 - 49.10
Avg. Volume1,122,631
Market Cap2.049B
Beta (5Y Monthly)1.01
PE Ratio (TTM)31.74
EPS (TTM)0.90
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-28% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for RCUS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arcus Biosciences, Inc.
    RCUS: What does Argus have to say about RCUS?ARCUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $19.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Simply Wall St.

    Arcus Biosciences, Inc.'s (NYSE:RCUS) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

    Most readers would already be aware that Arcus Biosciences' (NYSE:RCUS) stock increased significantly by 40% over the...

  • Business Wire

    Arcus Biosciences Announces New Employment Inducement Grants

    HAYWARD, Calif., June 24, 2022--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 22,850 shares of the Company’s common stock at an exercise price per share of $24.98, which was the closing price on June 23, 2022, and restricted stock units to acquire a total of 11,425 shares

  • Business Wire

    Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

    HAYWARD, Calif., May 31, 2022--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California. The fireside chat will take place on Thursday, June 16th, 2022 at 9:20 a.m. PT.